
Vivos Therapeutics (VVOS) Stock
Developer of oral appliances for sleep apnea. Here's the price, business snapshot, and what's worth knowing about Vivos Therapeutics in August 2026.
Vivos Therapeutics Inc (VVOS) is a micro‑cap healthcare company developing and commercialising oral appliance therapies and airway‑centred dental solutions aimed at treating sleep‑disordered breathing, including mild‑to‑moderate sleep apnoea. The company’s model centres on bespoke dental devices designed to expand the upper airway, distributed through a network of trained providers and partner clinics. With a market capitalisation of roughly $20.7 million, VVOS is a small, illiquid stock prone to price volatility; revenues and profitability have been variable as the business invests in clinical validation and market expansion. Key factors for investors include regulatory oversight, reimbursement environments, clinical adoption rates and intellectual property strength. Potential upside exists if clinical acceptance and sales scale, but risks are material and execution dependent. This is general educational information, not personalised investment advice. Values can fall as well as rise; prospective investors should assess suitability for their circumstances and consider professional guidance.
About This Stock
VIVOS THERAPEUTICS INC
VVOS
Current Price
$0.28
Potential 12 Month Profit
286.60%
Sector
N/A
Industry
N/A
Ticker
VVOS
Market Cap
$5.55M
Potential 12 Month Profit
286.60%
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VIVOS Therapeutics stock with a target price of $3.75, indicating strong growth potential.
Financial Health
Vivos Therapeutics is generating good revenue and profit margins, showing solid financial performance overall.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Sleep therapy growth
Rising awareness of sleep apnoea and interest in non‑CPAP options could create market opportunity, though clinical adoption and reimbursement will determine impact.
Small‑cap volatility
With a market cap around $20M, shares can be illiquid and volatile; this profile suits investors ready to accept higher risk and potential price swings.
Regulation and adoption
Regulatory approvals, clinical evidence and provider uptake are key growth levers—outcomes here can materially influence future performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.